CardioRisk IMT is the gold standard

CardioRisk IMT is the gold standard

Cardiovascular disease remains the leading cause of death globally, often striking without warning. Traditional risk assessment tools, while valuable, sometimes fail to detect early-stage atherosclerosis in asymptomatic individuals. This gap underscores the need for more precise diagnostic methods. Enter the CardioRisk Intima-Media Thickness (CIMT) test — a non-invasive ultrasound technique that measures the thickness of the carotid artery walls to evaluate cardiovascular health. Among providers, CardioRisk Laboratories stands out, offering a CIMT test renowned for its accuracy, reproducibility, and clinical relevance.

Understanding CIMT

CIMT involves using B-mode ultrasound to visualize and measure the thickness of the intima and media layers of the carotid artery, where this disease lives. These measurements serve as indicators of atherosclerotic burden and cardiovascular event risk. Unlike traditional assessments that may overlook subclinical atherosclerosis, CIMT provides direct visualization of arterial health, enabling early intervention.

The Superiority of CardioRisk's IMT

CardioRisk Laboratories has established itself as a leader in CIMT testing through several key differentiators:

Unparalleled Accuracy and Reproducibility

CardioRisk's IMT test boasts a reproducibility arithmetic difference of just 0.002mm (SD 0.02mm), the highest quality available from any laboratory, as documented in peer-reviewed literature. This precision ensures that even minute changes in arterial thickness are detected, allowing for timely interventions. Such accuracy is vital for monitoring disease progression and evaluating treatment efficacy.

Early Detection Capabilities

In a 10-year study encompassing 100,000 person-years, the technology utilized by CardioRisk (IMT) identified 98.6% of heart attacks and strokes before they occurred. This predictive power surpasses that of other non-invasive cardiovascular tests, enabling proactive management strategies that can significantly reduce adverse outcomes.

Non-Invasive and Patient-Friendly Procedure

The CIMT scan is brief — approximately 10 minutes — does not require the patient to disrobe, is non-invasive (no needles), and does not expose the patient to radiation. It is relatively inexpensive and provides valuable information about an individual's risk of experiencing a heart attack, stroke, or myocardial infarction.

Endorsements from Leading Health Organizations

Both the American Heart Association and the American College of Cardiology recommend CIMT measurement. This endorsement underscores the test's clinical validity and its role in comprehensive cardiovascular risk assessment.

Conclusion

CardioRisk Laboratories' IMT tests represent a significant advancement in cardiovascular diagnostics. Its unparalleled accuracy, predictive capabilities, and patient-friendly nature make it an invaluable tool in the fight against heart disease and stroke.

Sources

• Belcaro G, Nicolaides AN, Ramaswami G, et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study). Atherosclerosis. 2001;156(2):379–387. doi:10.1016/S0021-9150(00)00665-1
• Riches NO, Alder S, White GL, Druding R, Bond MG, De Michele M. Standardized ultrasound protocol, trained sonographers and digital system for carotid atherosclerosis screening. J Cardiovasc Med. 2010;11(9):683–688. doi:10.2459/JCM.0b013e328338919b
• Nicolaides A, Panayiotou AG. Screening for atherosclerotic cardiovascular risk using ultrasound. J Am Coll Cardiol. 2016;67(11):1275–1277. doi:10.1016/j.jacc.2016.01.016